Neratinib
2018-002
Phase 2 small_molecule active
Quick answer
Neratinib for Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PUMA BIOTECHNOLOGY, INC.
- Indication
- Triple Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active